EP1086091A4 - Inhibiteurs de vih integrase - Google Patents

Inhibiteurs de vih integrase

Info

Publication number
EP1086091A4
EP1086091A4 EP99926095A EP99926095A EP1086091A4 EP 1086091 A4 EP1086091 A4 EP 1086091A4 EP 99926095 A EP99926095 A EP 99926095A EP 99926095 A EP99926095 A EP 99926095A EP 1086091 A4 EP1086091 A4 EP 1086091A4
Authority
EP
European Patent Office
Prior art keywords
hiv integrase
integrase inhibitors
inhibitors
hiv
integrase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99926095A
Other languages
German (de)
English (en)
Other versions
EP1086091A1 (fr
Inventor
Steven D Young
John S Wai
Mark W Embrey
Thorsten E Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814925.5A external-priority patent/GB9814925D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1086091A1 publication Critical patent/EP1086091A1/fr
Publication of EP1086091A4 publication Critical patent/EP1086091A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99926095A 1998-06-03 1999-06-01 Inhibiteurs de vih integrase Withdrawn EP1086091A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8784698P 1998-06-03 1998-06-03
US87846P 1998-06-03
GBGB9814925.5A GB9814925D0 (en) 1998-07-09 1998-07-09 HIV integrase inhibitors
GB9814925 1998-07-09
PCT/US1999/012094 WO1999062897A1 (fr) 1998-06-03 1999-06-01 Inhibiteurs de vih integrase

Publications (2)

Publication Number Publication Date
EP1086091A1 EP1086091A1 (fr) 2001-03-28
EP1086091A4 true EP1086091A4 (fr) 2001-10-10

Family

ID=26314001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99926095A Withdrawn EP1086091A4 (fr) 1998-06-03 1999-06-01 Inhibiteurs de vih integrase

Country Status (5)

Country Link
EP (1) EP1086091A4 (fr)
JP (1) JP2002517390A (fr)
AU (1) AU757409B2 (fr)
CA (1) CA2333771A1 (fr)
WO (1) WO1999062897A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
JP3929244B2 (ja) 1998-12-25 2007-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する芳香族ヘテロ環誘導体
JP3616628B2 (ja) 2001-03-01 2005-02-02 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
BR0211750A (pt) 2001-08-10 2004-10-13 Shionogi & Co Agente antiviral
EP1441734B1 (fr) * 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Inhibiteurs de l'integrase du vih a base de dihydroxypyrimidine carboxamide
NZ533057A (en) 2001-10-26 2005-11-25 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
WO2003077857A2 (fr) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(benzyl substitue)-8-hydroxy-1,6-naphtyridine-7-carboxamides utiles comme inhibiteurs de l'integrase du vih
EP1541558B1 (fr) 2002-08-13 2008-08-13 Shionogi & Co., Ltd. Composes heterocycliques a activite inhibitrice de l'integrase du vih
DE602005023717D1 (de) 2004-03-10 2010-11-04 Usa Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc)
EP2046328A4 (fr) 2006-07-19 2009-10-28 Univ Georgia Res Found Dicétoacides de pyridinone : inhibiteurs de la réplication du vih dans une thérapie combinée
US8664255B2 (en) 2008-10-20 2014-03-04 The Texas A&M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
WO2011071849A2 (fr) 2009-12-07 2011-06-16 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentylcarboxamides : inhibiteurs de l'intégrase du vih ayant des applications thérapeutiques
US10414747B2 (en) 2016-10-04 2019-09-17 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US20240360113A1 (en) * 2021-08-10 2024-10-31 Texas Heart Institute Aminoaryl-integrin agonists compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069111A1 (fr) * 1998-03-26 2001-01-17 SHIONOGI & CO., LTD. Derives d'indole exer ant une activite antivirale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56100784A (en) * 1980-01-16 1981-08-12 Yoshitomi Pharmaceut Ind Ltd Indolizine derivative
US4336397A (en) * 1980-12-29 1982-06-22 Merck & Co., Inc. 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis
US5475109A (en) * 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US5470862A (en) * 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069111A1 (fr) * 1998-03-26 2001-01-17 SHIONOGI & CO., LTD. Derives d'indole exer ant une activite antivirale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO9962897A1 *
TOMASSINI ET AL: "Inhibition of", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 38, no. 12, December 1994 (1994-12-01), pages 2827 - 2837, XP002119719, ISSN: 0066-4804 *
WAI J S ET AL: "4-Aryl-2,4-dioxobutanoic Acid Inhibitors of HIV-1 Integrase and Viral Replication in Cells", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 26, 28 December 2000 (2000-12-28), pages 4923 - 4926, XP002174189, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
AU757409B2 (en) 2003-02-20
WO1999062897A1 (fr) 1999-12-09
EP1086091A1 (fr) 2001-03-28
AU4225599A (en) 1999-12-20
JP2002517390A (ja) 2002-06-18
CA2333771A1 (fr) 1999-12-09

Similar Documents

Publication Publication Date Title
GB9900416D0 (en) Inhibitors
AU3118200A (en) Hiv integrase inhibitors
EP1086091A4 (fr) Inhibiteurs de vih integrase
AU6616400A (en) Hiv integrase inhibitors
EP1082121A4 (fr) Inhibiteurs de vih integrase
EP1083897A4 (fr) Inhibiteurs de vih integrase
PL370664A1 (en) Hiv integrase inhibitors
AU6989501A (en) Hiv integrase inhibitors
EP1050583A4 (fr) Inhibiteurs d'infections a vih
AU8009900A (en) Hiv integrase inhibitors
GB9621974D0 (en) HIV integrase inhibitors
IL148889A0 (en) Set defence means
EP1153022A4 (fr) Inhibiteurs de protease
AU6271098A (en) Hiv integrase inhibitors
GB9815925D0 (en) HIV Intergrase inhibitors
GB2389113B (en) B-secretase inhibitor
GB9904419D0 (en) 4-aminoquinolines
GB9814925D0 (en) HIV integrase inhibitors
GB9814930D0 (en) HIV integrase inhibitors
GB9800226D0 (en) HIV integrase inhibitors
GB9815175D0 (en) HIV integrase inhibitors
IL132998A0 (en) Vif-derived hiv protease inhibitors
DE69940886D1 (en) Hiv impfstoff
GB9707492D0 (en) HIV integrase inhibitors
GB9625326D0 (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010103;LT PAYMENT 20010103;LV PAYMENT 20010103;MK PAYMENT 20010103;RO PAYMENT 20010103;SI PAYMENT 20010103

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 333/74 A, 7C 07D 333/56 B, 7C 07D 333/22 B, 7C 07D 277/04 B, 7C 07D 277/18 B, 7A 61K 31/38 B, 7A 61K 31/425 B, 7C 07D 333/24 B, 7C 07D 333/32 B, 7C 07D 333/34 B, 7C 07D 333/36 B, 7C 07D 333/38 B, 7C 07D 409/12 B, 7C 07D 409/06 B, 7C 07D 277/56 B, 7C 07D 333/68 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010827

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040427